Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine
the safety and efficacy of ssCART-19 in the treatment of patients with CD19 positive relapsed
or refractory acute lymphoblastic leukemia.